Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Oleandomycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 12/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.94 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.68 |
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | MLNR | O43193 | 4/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oleandomycin SCHEMBL5033021 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAABCB1USP2MLNR | |
| Oleandomycin SCHEMBL3717 | 0.97 | CYP3A4 (1.00) | CYP3A4LMNAABCB1USP2MLNR | |
| Oleandomycin SCHEMBL3716 | 0.97 | CYP3A4 (1.00) | CYP3A4LMNAABCB1USP2MLNR | |
| Oleandomycin SCHEMBL29684259 | 0.97 | CYP3A4 (1.00) | CYP3A4LMNAABCB1USP2MLNR | |
| Oleandomycin SCHEMBL10028439 | 0.97 | CYP3A4 (1.00) | CYP3A4LMNAABCB1USP2MLNR | |
| Oleandomycin SCHEMBL9807053 | 0.96 | CYP3A4 (0.99) | CYP3A4LMNAABCB1USP2MLNR | |
| Oleandomycin SCHEMBL950913 | 0.95 | CYP3A4 (0.96) | CYP3A4LMNAABCB1USP2MLNR | |
| SCHEMBL11029029 | 0.89 | CYP3A4 (0.85) | CYP3A4LMNAABCB1USP2MLNR | |
| Diproleandomycin SCHEMBL2109038 | 0.84 | CYP3A4 (0.78) | CYP3A4LMNAABCB1USP2MLNR | |
| SCHEMBL5551907 | 0.83 | CYP3A4 (0.74) | CYP3A4LMNAABCB1USP2MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113559264-A | Methods of treating microbial infections including mastitis | 罗达制药公司 | 2021-10-29 | — | — | CN | claimed |
| CN-113144197-A | Method of treating topical microbial infections | 罗达制药公司 | 2021-07-23 | — | — | CN | claimed |
| EP-2953624-B1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LUODA PHARMA LTD (IE) | 2019-08-21 | — | — | EP | claimed |
| US-20190038655-A1 | CHEMICALS AND METHODS TO PREVENT AND TREAT TGF-BETA MEDIATED ACTIVATION OF FIBROBLASTS TO REDUCE AND TREAT CANCER AND FIBROSIS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2019-02-07 | — | — | US | claimed |
| EP-3411045-A1 | CHEMICALS AND METHODS TO PREVENT AND TREAT TGF-BETA MEDIATED ACTIVATION OF FIBROBLASTS TO REDUCE AND TREAT CANCER AND FIBROSIS | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College (US) | 2018-12-12 | — | — | EP | claimed |
| WO-2017136515-A1 | CHEMICALS AND METHODS TO PREVENT AND TREAT TGF-BETA MEDIATED ACTIVATION OF FIBROBLASTS TO REDUCE AND TREAT CANCER AND FIBROSIS | CARDELLI JAMES ALLEN (US) | 2017-08-10 | — | — | WO | claimed |
| US-20170128379-A1 | MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2017-05-11 | — | — | US | claimed |
| US-20160000748-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | Luoda Pharma Limited (IE) | 2016-01-07 | — | — | US | claimed |
| WO-2016001937-A2 | MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2016-01-07 | — | — | WO | claimed |
| US-20150366797-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | Luoda Pharma Limited (IE) | 2015-12-24 | — | — | US | claimed |
| EP-2953623-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | Luoda Pharma Pty Ltd (AU) | 2015-12-16 | — | — | EP | claimed |
| EP-2953624-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | Luoda Pharma Pty Ltd (AU) | 2015-12-16 | — | — | EP | claimed |
| WO-2014121342-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | LUODA PHARMA PTY LIMITED (AU) | 2014-08-14 | — | — | WO | claimed |
| US-20100221245-A1 | TOPICAL SKIN CARE COMPOSITION | DERMADOCTOR, LLC | 2010-09-02 | — | — | US | claimed |
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | UNIV ARIZONA (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260014384-A1 | RESORBABLE NONWOVEN POUCHES FOR MEDICAL DEVICE IMPLANTS | TEPHA, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-12440687-B2 | Resorbable nonwoven pouches for medical device implants | TEPHA, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-4539234-A | Urethral catheter capable of preventing urinary tract infection and process for producing the same | UNITIKA LTD. (JP) | 1985-09-03 | — | — | US | disclosed |
| EP-0065884-A1 | Urethral catheter capable of preventing urinary tract infection and process for producing the same | UNITIKA LTD. (JP) | 1982-12-01 | — | — | EP | disclosed |
| US-4102806-A | DISPERSION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000748-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | TSLP, CCL11, IL17A | KCNH2 1514/4885CYP3A4 4224/4885LMNA 4594/4885 |
| US-20150366797-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LCT, TSLP, MLEC | KCNH2 737/4885CYP3A4 4664/4885LMNA 4632/4885 |
| US-20260014384-A1 | RESORBABLE NONWOVEN POUCHES FOR MEDICAL DEVICE IMPLANTS | MLN, TNNC1, VIP | KCNH2 691/4885CYP3A4 700/4885LMNA 3992/4885 |
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | DNMT3L, DNMT3A, DNMT1 | KCNH2 4126/4885CYP3A4 3633/4885LMNA 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.